

C-RAD IS ADVANCING RADIOTHERAPY IN LATIN AMERICA IN MEXICO AND WINS 10 MSEK ORDER

C-RAD is pleased to announce a landmark order for its advanced Catalyst+ HD and Sentinel systems in Mexico. The systems are part of a larger order for state-of-the-art linear accelerators from Elekta AB, placed by Hospital Angeles Health System, one of Mexico's leading healthcare networks. The total order value for the Catalyst+ HD and Sentinel systems amounts to 10 MSEK.

The equipment package includes multiple linear accelerators, each integrated with C-RAD's Catalyst+ HD SGRT system used in precision patient positioning, motion monitoring, and Deep Inspiration Breath Hold (DIBH) treatments. The order also includes Sentinel 4DCT, which enhances the treatment planning process. By combining these technologies, C-RAD's solutions help enable optimal treatment outcomes while minimizing patients' exposure to non-prescribed radiation.

"This is a pivotal step in making Surface Guided Radiation Therapy (SGRT) the standard of care in Mexico. I want to commend Hospital Angeles Health System for investing in advanced radiation oncology technologies, including the Catalyst+ HD system, which supports Deep Inspiration Breath Hold techniques and enhances the overall safety and accuracy of treatment. We are excited about our growing presence in this market alongside our partner Elekta, and we are honoured that C-RAD's technology has been selected for use in multiple centres across Mexico," says Cecilia de Leeuw, CEO and President of C-RAD.

Integrating Catalyst+ HD systems within the hospital's sophisticated linear accelerators represents a significant advancement for cutting-edge radiotherapy technologies in the region. Streamlining the entire radiotherapy workflow allows superior treatment precision without additional radiation risk, reinforcing C-RAD's commitment to patient safety and superior treatment outcomes

Delivery is expected to start during next year and will continue over several quarters.

For further information:

Cecilia de Leeuw, CEO, +46 (0)795 85 66 77, investors@c-rad.com
Linda Frölen, CFO, +46 (0)703 03 32 53, investors@c-rad.com

About C-RAD

C-RAD develops surface-guided imaging solutions for radiation therapy to allow highly accurate dose delivery to the tumor, and at the same time, to protect healthy tissue from unwanted exposure. Using high-speed 3D cameras combined with augmented reality, C-RAD supports the initial patient setup process and monitors the patient's motion during treatment to ensure high confidence, an efficient workflow, and improved accuracy. C-RAD monitors the patient's motion without the use of tattoos or additional imaging dose, to deliver the highest level of patient safety and comfort.

C-RAD. Inspiring excellence in cancer treatment.

C-RAD AB is listed on NASDAQ Stockholm.

For more information on C-RAD, please visit <http://www.c-rad.com>

Attachments

C-RAD is advancing radiotherapy in Latin America in Mexico and wins 10 MSEK order